Fact Sheet

About Illumina

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible, and scalable, with industry-leading support and service.

We strive to meet this challenge by placing a high value on collaborative interactions, rapid delivery of solutions, and meeting the needs of our customers.

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

Download Illumina @ a Glance Fact Sheet
Quick facts
  • Website:
    illumina.com
  • Ticker symbol:
    ILMN
  • Headquarters:
    San Diego, California, USA
  • Number of employees:
    ~10,000 globally
  • 2022 revenue1:
    $4.58B USD
  • Illumina @ a Glance
    Fact Sheet

The Illumina mission

We take our mission seriously and ingrain it in everything we do.

Our mission statement:
To improve human health by unlocking the power of the genome.

Leading-edge products and services

Illumina has developed a comprehensive line of products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. Our broad portfolio of leading-edge sequencing and array-based solutions addresses a range of genomic complexity and throughput, enabling researchers to select the best solution for their scientific challenge.

Instruments

  • NovaSeq Sequencing Systems
  • NextSeq Sequencing Systems
  • NextSeqDX Sequencing System
  • MiSeq Sequencing System
  • MiSeqDx Sequencing System
  • MiniSeq Sequencing System
  • iSeq 100 System
  • iScan Array Scanner

Assays

  • AmpliSeq for Illumina
  • TruSeq, TruSight, and Nextera technologies
  • Infinium genotyping and methylation assays

Where we operate

  • San Diego, California, USA
  • Foster City, California, USA
  • Hayward, California, USA
  • Baltimore, Maryland, USA
  • Madison, Wisconsin, USA
  • São Paulo, Brazil
  • Cambridge, UK
  • Mechelen, Belgium
  • Évry, France
  • Rennes, France
  • Berlin, Germany
  • Milan, Italy
  • Tel Aviv, Israel
  • Eindhoven, Netherlands
  • Moscow, Russia
  • Istanbul, Turkey
  • Dubai, UAE
  • Beijing, China
  • Shanghai, China
  • Guangzhou, China
  • Hangzhou, China
  • Taipei City, China
  • Osaka, Japan
  • Tokyo, Japan
  • Singapore
  • Melbourne, Australia
  • Seoul, South Korea

Illumina management team

  • Charles Dadswell
    Interim CEO and General Counsel
  • Alex Aravanis, MD, PhD
    Chief Technology Officer, Head of Research and Product Development
  • Nicole Berry
    Head of Region—Americas
  • Phil Febbo, MD
    Chief Medical Officer
  • John Frank
    Chief Public Affairs Officer
  • Joydeep Goswami, PhD
    Chief Financial Officer, Chief Strategy and Corporate Development Officer
  • Aimee Hoyt
    Chief People Officer
  • Kevin Pegels
    Chief of Global Operations
  • Li Qing
    Head of Region—Greater China
  • Kathryne Reeves
    Chief Marketing Officer
  • Carissa Rollins
    Chief Information Officer
  • Salli Schwartz
    Vice President of Investor Relations
  • Susan Tousi
    Chief Commercial Officer
  • Bas Verhoef
    Head of Region–Europe
  • Gretchen Weightman
    Head of Region—Asia Pacific, Middle East, & Africa
  1. 2022 Annual Revenue provided in February 2023